Point State Capital LP Mirati Therapeutics, Inc. Transaction History

Point State Capital LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$132.01 - $190.29 $1.15 Million - $1.66 Million	-8,700 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$132.13 - $177.45 $1.15 Million - $1.54 Million	8,700 New	8,700 $1.54 Million
Q4 2018 Feb 14, 2019	SELL	$32.0 - $47.43 $7.73 Million - $11.5 Million	-241,625 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$47.1 - $62.7 $11.4 Million - $15.1 Million	241,625 New	241,625 $11.4 Million
Q2 2018 Aug 14, 2018	SELL	$26.05 - $52.4 $7.78 Million - $15.6 Million	-298,500 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$17.2 - $34.95 $5.13 Million - $10.4 Million	298,500 New	298,500 $9.16 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Point State Capital LP, based on Form 13F filings with the SEC.

Stay updated on Point State Capital LP with notifications on news.